Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses

被引:186
作者
Ioannidis, John P. A. [1 ,2 ,3 ]
Panagiotou, Orestis A. [3 ]
机构
[1] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[3] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 21期
关键词
CORONARY-HEART-DISEASE; HELICOBACTER-PYLORI INFECTION; PROSTATE-CANCER RISK; C-REACTIVE PROTEIN; GROWTH-FACTOR-I; PLATELET GLYCOPROTEIN RECEPTOR; TYPE-2; DIABETES-MELLITUS; LYMPHOTOXIN-ALPHA GENE; BREAST-CANCER; MYOCARDIAL-INFARCTION;
D O I
10.1001/jama.2011.713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Many biomarkers are proposed in highly cited studies as determinants of disease risk, prognosis, or response to treatment, but few eventually transform clinical practice. Objective To examine whether the magnitude of the effect sizes of biomarkers proposed in highly cited studies is accurate or overestimated. Data Sources We searched ISI Web of Science and MEDLINE until December 2010. Study Selection We included biomarker studies that had a relative risk presented in their abstract. Eligible articles were those that had received more than 400 citations in the ISI Web of Science and that had been published in any of 24 highly cited biomedical journals. We also searched MEDLINE for subsequent meta-analyses on the same associations (same biomarker and same outcome). Data Extraction In the highly cited studies, data extraction was focused on the disease/outcome, biomarker under study, and first reported relative risk in the abstract. From each meta-analysis, we extracted the overall relative risk and the relative risk in the largest study. Data extraction was performed independently by 2 investigators. Results We evaluated 35 highly cited associations. For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and only twice was the effect size estimate stronger in the largest than in the highly cited study. For 29 of the 35 (83%) highly cited studies, the corresponding meta-analysis found a smaller effect estimate. Only 15 of the associations were nominally statistically significant based on the largest studies, and of those only 7 had a relative risk point estimate greater than 1.37. Conclusion Highly cited biomarker studies often report larger effect estimates for postulated associations than are reported in subsequent meta-analyses evaluating the same associations. JAMA. 2011;305(21):2200-2210 www.jama.com
引用
收藏
页码:2200 / 2210
页数:11
相关论文
共 124 条
[91]   CHOLESTEROL LOWERING TRIALS IN CORONARY HEART-DISEASE - FREQUENCY OF CITATION AND OUTCOME [J].
RAVNSKOV, U .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6844) :15-19
[92]   C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women [J].
Ridker, PM ;
Hennekens, CH ;
Buring, JE ;
Rifai, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (12) :836-843
[93]   Reporting bias in diagnostic and prognostic studies: Time for action [J].
Rifai, Nader ;
Altman, Douglas G. ;
Bossuyt, Patrick M. .
CLINICAL CHEMISTRY, 2008, 54 (07) :1101-1103
[94]  
Riley R D, 2003, Health Technol Assess, V7, P1
[95]   IGF-1, IGFBP-3 and breast cancer risk in women:: The European Prospective Investigation into Cancer and Nutrition (EPIC) [J].
Rinaldi, S. ;
Peeters, P. H. M. ;
Berrino, F. ;
Dossus, L. ;
Biessy, C. ;
Olsen, A. ;
Tjonneland, A. ;
Overvad, K. ;
Clavel-Chapelon, F. ;
Boutron-Ruault, M. C. ;
Tehard, B. ;
Nagel, G. ;
Linseisen, J. ;
Boeing, H. ;
Lahmann, P. H. ;
Trichopoulou, A. ;
Trichopoulos, D. ;
Koliva, M. ;
Palli, D. ;
Panico, S. ;
Tumino, R. ;
Sacerdote, C. ;
van Gils, C. H. ;
van Noord, P. ;
Grobbee, D. E. ;
Bueno-de-Mesquita, H. B. ;
Gonzalez, C. A. ;
Agudo, A. ;
Chirlaque, M. D. ;
Barricarte, A. ;
Larranaga, N. ;
Quiros, J. R. ;
Bingham, S. ;
Khaw, K. T. ;
Key, T. ;
Allen, N. E. ;
Lukanova, A. ;
Slimani, N. ;
Saracci, R. ;
Riboli, E. ;
Kaaks, R. .
ENDOCRINE-RELATED CANCER, 2006, 13 (02) :593-605
[96]   Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies [J].
Rinaldi, Sabina ;
Cleveland, Rebecca ;
Norat, Teresa ;
Biessy, Carine ;
Rohrmann, Sabine ;
Linseisen, Jakob ;
Boeing, Heiner ;
Pischon, Tobias ;
Panico, Salvatore ;
Agnoli, Claudia ;
Palli, Domenico ;
Tumino, Rosario ;
Vineis, Paolo ;
Peeters, Petra H. M. ;
van Gils, Carla H. ;
Bueno-de-Mesquita, Bas H. ;
Vrieling, Alina ;
Allen, Naomi E. ;
Roddam, Andrew ;
Bingham, Sheila ;
Khaw, Kay-Tee ;
Manjer, Jonas ;
Borgquist, Signe ;
Dumeaux, Vanessa ;
Gram, Inger Torhild ;
Lund, Eiliv ;
Trichopoulou, Antonia ;
Makrygiannis, Georgios ;
Benetou, Vassiliki ;
Molina, Esther ;
Donate Suarez, Ignacio ;
Barricarte Gurrea, Aurelio ;
Gonzalez, Carlos A. ;
Tormo, Maria-Jose ;
Altzibar, Jone M. ;
Olsen, Anja ;
Tjonneland, Anne ;
Gronbaek, Henning ;
Overvad, Kim ;
Clavel-Chapelon, Francoise ;
Boutron-Ruault, Marie-Christine ;
Morois, Sophie ;
Slimani, Nadia ;
Boffetta, Paolo ;
Jenab, Mazda ;
Riboli, Elio ;
Kaaks, Rudolf .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (07) :1702-1715
[97]   Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk [J].
Rivera, A ;
Fisher, SA ;
Fritsche, LG ;
Keilhauer, CN ;
Lichtner, P ;
Meitinger, T ;
Weber, BHF .
HUMAN MOLECULAR GENETICS, 2005, 14 (21) :3227-3236
[98]  
Ross D, 1996, BRIT MED J, V313, P686
[99]   Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis [J].
Rowlands, Mari-Anne ;
Gunnell, David ;
Harris, Ross ;
Vatten, Lars J. ;
Holly, Jeff M. P. ;
Martin, Richard M. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (10) :2416-2429
[100]  
Ruige JB, 1998, CIRCULATION, V97, P996